New hope for Hard-to-Treat cancers: targeted drug enters human trials
NCT ID NCT07417189
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called ABSK141 in people with advanced solid tumors that have a specific gene change called KRAS G12D. The goal is to find a safe dose and see if the drug can shrink tumors. About 401 adults with cancers like colorectal, lung, or pancreatic cancer will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, 201321, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pancreatic Cancer's inflammatory footprint be stopped?
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can your own immune cells beat advanced cancer?
- Can we predict chemo brain before it happens?
- Can a new immunotherapy combo outsmart advanced lung cancer?